Director Philip Wagenheim of Immunome Inc. (NASDAQ:IMNM) reported two stock sales in a Form 4 filing with the Securities and Exchange Commission, disposing of a combined 65,000 shares of common stock for total proceeds of $1,335,626.
The first transaction took place on March 20, 2026, when Wagenheim sold 36,800 shares in trades executed at prices ranging from $20.07 to $20.96. The second occurred on March 23, 2026, when he sold 28,200 shares at prices between $20.15 and $20.84. After those sales, Wagenheim is listed as directly owning 341,147 shares of Immunome.
At the time of the filing, Immunome's shares were trading at $20.76, a price point that represents a 155% gain over the past year.
Market context and research views
Investor commentary highlighted in the filing notes an InvestingPro analysis that currently views the stock as overvalued relative to its Fair Value. The platform also flags the company’s share price as having high volatility, characterizing that volatility as one of 11 ProTips provided to subscribers.
Separately, investment bank H.C. Wainwright has initiated coverage of Immunome with a Buy rating and a $40.00 price target. In its assessment, the firm emphasized Immunome’s strategy of building a portfolio of oncology assets and pointed to the potential of the company’s lead asset, varegacestat. H.C. Wainwright highlighted varegacestat as a candidate for a superior gamma-secretase inhibitor in the treatment of desmoid tumors when compared to the currently approved therapy, Ogsiveo.
The firm’s report also noted Immunome’s positioning across both solid tumor and hematologic indications, framing those elements as differentiators in the company’s approach to oncology development.
What is known and what remains limited
- Confirmed facts: The Form 4 discloses two sales totaling 65,000 shares for $1,335,626; the sales occurred on March 20 and March 23, 2026; Wagenheim retains a direct stake of 341,147 shares.
- Market signals: The stock was trading at $20.76 and has appreciated 155% over the prior year at the time of the report.
- Analyst notes: InvestingPro flags overvaluation and volatility; H.C. Wainwright initiated Buy coverage with a $40.00 target and emphasized the potential of varegacestat versus Ogsiveo for desmoid tumors.
Where the public record is limited, the filing does not provide an explanation for the director’s sales beyond what is disclosed on the Form 4. The available disclosures and third-party research are the basis for the current market assessment.